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I. INTRODUCTION 
Right before our eyes, the rules of the game of life will become 
even more complicated. While the prolific English board game publisher 
John Wallis theorized there to be seven sequential stages of human life, 
this historical chronology will be significantly disrupted with the advent 
of three-dimensional (3D) bioprinting.1 Three-dimensional bioprinting 
has provided a means to manufacture living tissues and organs, creating 
the fundamental pieces that sustain life.2 This “game changer” invites 
the potential to defy the natural progression of life by enhancing 
humans’ overall health, vitality, and average life expectancy. 
One of the greatest promises with the arrival of 3D bioprinting is an 
* Katherine Smith is a candidate for Juris Doctor at The University of Akron School of Law. She
received her B.S. in Biomedical Engineering and a minor in Applied Mathematics from The 
University of Akron.  
1. Cornell University, The New Game of Human Life. London: John Wallis, 1790, DIVISION 
OF RARE & MANUSCRIPT COLLECTIONS (2004), http://rmc.library.cornell.edu/
games/promoting/4.html (stating that “[t]he New Game of Human Life created by John Wallis 
encouraged young players to develop proper moral character, learning the exigencies of the seven 
stages of life, from ‘Infancy’ to ‘Dotage,’ while navigating the paths of vice and virtue. Players 
advance or forfeit according to the moral nature of the character represented in the square they land 
on.”). Charles Hull, Stereolithography (3D Printing), NATIONAL INVENTORS HALL OF FAME (2014), 
http://invent.org/inductees/hull-charles/ (Charles W. Hull first invented commercial 3D printing in 
1986. His method, which he titled “sterolithography,” involved sequentially printing thin layers of 
an ultraviolet cured-material to form a solid 3D structure. 3D bioprinting is the future of this long-
standing technology.). Wai Hon Wah, Introduction to STL Format, POLYTECHNICAL UNIVERSITY 
OF HONG KONG (1999), http://download.novedge.com/Brands/FPS/Documents/
Introduction_To_STL_File_Format.pdf (describing standard tessellation language (“STL”) as a 
facet-based embodiment that approximates surface and solid items only (points, lines, curves, and 
attributes such as layers and color in the CAD system will be ignored during the output process). 
Facets delineate the surface of a 3D object. Most 3D printers can only use a model if it has been 
exported to STL format.). Sean V. Murphy & Anthony Atala, 3D bioprinting of tissues and organs, 
NATURE BIOTECHNOLOGY, 773 (2014), http://www.nature.com/nbt/journal/
v32/n8/full/nbt.2958.html (also asserting that “[t]he development of solvent-free, aqueous-based 
systems enabled the direct printing of biological materials into 3D scaffolds that could be used for 
transplantation with or without seeded cells. The next step was 3D bioprinting as a form of tissue 
engineering, made possible by recent advances in 3D printing technology, cell biology and materials 
science. A related development was the application of 3D printing to produce medical devices such 
as stents and splints for use in the clinic.”). 
2. Murphy & Atala, supra note 1 (addressing that “[the] complexities [of bioprinting]
require the integration of technologies from the fields of engineering, biomaterials science, cell 
biology, physics and medicine. 3D bioprinting has already been used for the generation and 
transplantation of several tissues, including multilayered skin, bone, vascular grafts, tracheal splints, 
heart tissue and cartilaginous structures. Other applications include developing high-throughput 3D-
bioprinted tissue models for research, drug discovery and toxicology.”).  
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answer to expediting the organ donor transplant process.3 This promise 
will help eradicate desperation, despair, and fear of premature death 
from patients awaiting organ donations. According to the Organ 
Procurement & Transplantation Network (OPTN), there are currently 
over 120,000 waiting list candidates in the United States.4 Also 
astonishing is that approximately 21 people die each day waiting for an 
organ transplant, a consequence of there being just under 12,000 donors 
and stringent regulations.5 3D bioprinting would provide an ideal 
solution to the central issue—the availability of a donor—by eliminating 
the issue altogether. Never again would a family member have to 
sacrifice a vital organ or someone in the final stages of a fatal disease 
have to live with the notion that an organ may not come in time. The 
wait time would be little more than the amount of time it would take to 
print an organ; patients could be given a near-exact waiting time, putting 
their minds and their families’ minds at ease. 
Both federal and state legislatures have passed acts that attempt to 
provide safe and equitable systems for the allocation, distribution, and 
transplantation of donated organs.6 In 1984, Congress enacted the 
National Organ Transplant Act (NOTA), which created the OPTN and 
criminalized the exchange of human organs for valuable consideration.7 
3. Tanya Lewis, 3D-Printed Human Embryonic Stem Cells Created for First Time, LIVE 
SCIENCE, (Feb. 5, 2013, 8:27 AM ET), http://www.livescience.com/26865-3d-printed-embryonic-
stem-cells.html (presenting a second consideration: those who do receive transplants run the risk of 
unforeseen medical complications and organ rejection. However, 3D bioprinting may solve that 
issue as well; it may be able to incorporate a patient’s own stem cells to regenerate a living organ. 
Researchers at Heriot-Watt University in Edinburgh have created a cellular printer that uses living 
embryonic stem cells as its “ink.” The researchers hope to use this new printing method “to make 
3D human tissues for testing new drugs, grow organs, or ultimately print cells directly inside the 
body.” Ultimately, rejection would become moot, reducing the number of complications and 
accelerating a patient’s recovery time and reentry into their usual routine.).  
4. About Us, UNITED NETWORK FOR ORGAN SHARING, http://www.unos.org/about/
index.php (last visited Nov. 30, 2015) (stating that the United Network for Organ Sharing (UNOS) 
is a private, non-profit organization that manages the nation’s organ transplant system and maintains 
the national registry for organ matching under contract with the federal government.). Organ 
Procurement and Transplantation Network, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES, 
http://optn.transplant.hrsa.gov (last visited Nov. 30, 2015) (an official U.S. Government website 
managed by the Health and Resources Services Administration, U.S. Department of Health & 
Human Services). 
5. Organ Procurement and Transplantation Network, supra note 4. 
6. Legislation and Policy, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES,
http://www.organdonor.gov/legislation/ (last visited Nov. 30, 2015).  
7. Selected Statutory and Regulatory History of Organ Transplantation, U.S. DEPARTMENT 
OF HEALTH & HUMAN SERVICES, http://organdonor.gov/legislation/legislationhistory.html (last 
visited Nov. 30, 2015) (asserting that NOTA also provided for the establishment of the Task Force 
on Organ Transplantation, created the Scientific Registry of Transplant Recipients, and formed an 
administrative unit within the Department of Health and Human Services to administer all 
3
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Accordingly, under Section 301 of NOTA, any individual convicted of 
buying or selling a human organ faces a five-year prison sentence and/or 
a sizeable fine.8 All 50 states have adopted the Uniform Anatomical Gift 
Act (UAGA), which explicitly prohibits the purchase and sale of organs 
if removal of the organ is intended after death.9 Notably, some states 
have included a provision prohibiting the purchase and sale of organs by 
living donors if removal is to occur before death.10 
Consequently, with the introduction of such a capable technology 
comes concern for compliance with the law. This Note begins with a 
technical discussion of the technology of bioprinting and explains 
current engineering techniques and capabilities. Part II contains an in-
depth survey of federal and state laws governing organ donation, 
analyzing the evolution of organ donor law. This part also presents 
arguments for and against live donor organ sales and compares and 
contrasts policy arguments dealing with the potentiality that a bioprinted 
organ will indeed be determined to be “an organ transplant for valuable 
consideration.” Part III turns to a discussion of the applicability of 
current law to 3D bioprinting, delving into the issue of whether federal 
NOTA restrictions will be applied to the sale of 3D bioprinted organs. 
This disturbing construction will mean that a manufactured organ will 
qualify as a “human organ” under Section 310 of NOTA such that 
selling the printed organs would violate the statute. Whether 3D printed 
organs would be considered “experimental treatment” is also discussed 
for purposes of whether this would present a roadblock to immediate 
patient access to manufactured organs. Part IV of this Note identifies the 
ethical implications associated with manufactured organs, specifically 
the potential for black market operations, and suggests that these 
implications may detract from the countless benefits bioprinted organs 
could provide. Finally, Part V speculates that 3D printed organs will, 
indeed, be construed to qualify as “human organs” under NOTA and that 
the NOTA limitations on the sale of human organs will apply to the sale 
of 3D bioprinted organs. 
activities). 
8. FindLaw, Can I Sell an Organ?, THOMSON REUTERS, http://healthcare.findlaw.com/
patient-rights/can-i-sell-an-organ.html (last visited Nov. 30, 2015).  
9. Robyn S. Shapiro, Legal Issues in Payment of Living Donors for Solid Organs, 7 
CURRENT OPINION ON ORGAN TRANSPLANTATION, 375-79 (2002), available at 
http://www.americanbar.org/publications/human_rights_magazine_home/human_rights_vol30_200
3/spring2003/hr_spring03_livingdonors.html.  
10. Id.
4
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II. 3D BIOPRINTING: ITS HISTORY AND ITS PROMISE
This Note begins by discussing the origin and history of 3D 
bioprinting. Part II.A explains 3D printing at its basic level and describes 
how a 3D printed model is produced. Part II.B provides an overview of 
the three main production methods of 3D printing. Part II.C gives 
examples of how 3D printing can be applied in various industries. Part 
II.D discusses researchers’ goal of printing cells to form functional
tissues and the challenges that come along with doing so. Part II.E 
contrasts traditional tissue engineering with 3D bioprinting tissue. Part 
II.F explains two methods of 3D bioprinting, extrusion printing and
thermal ink-jet printing, as well as several details to consider when 3D 
bioprinting. Part II.G describes and provides examples of present-day 
success with manufacturing functional tissues and also discusses the 
limits researchers have faced in light of their success. Part II.H 
concludes by discussing the current financial state of funding 3D 
bioprinting research in light of other medical research and alludes to new 
monetary incentives for engaging in 3D bioprinting research. 
A. The Basics of 3D Printing 
Three-dimensional printing, also known as “rapid prototyping” or 
“additive manufacturing,” provides a process for constructing 3D objects 
from a digital file known as a computer-aided design (CAD) model.11 A 
CAD model is a digital, 3D representation of a physical object, typically 
created through the use of 3D modeling software. Generally, CAD 
models can be used for animation or visualization of an object, to make 
design changes to a product, to perform dimensional or comparative 
analysis of an object, or even for finite element analysis and 
computational fluid dynamics analysis.12 Regarding 3D printing, 
11. What Is 3D Printing, THE 3D PRINTING ASSOCIATION, 
https://www.the3dprintingassociation.com/what-is-3d-printing (last visited Nov. 30, 2015).  
12. Almost Everything You Always Wanted to Know About 3D Scanning, DIRECT 
DIMENSIONS, http://www.dirdim.com/lm_everything.htm (last visited Nov. 30, 2015). Finite 
Element Analysis, AUTODESK, http://usa.autodesk.com/adsk/servlet/
item?siteID=123112&id=17670721 (last visited Nov. 30, 2015) (explaining that “[f]inite element 
analysis (FEA) is a computerized method for predicting how a product reacts to real-world forces, 
vibration, heat, fluid flow, and other physical effects. Finite element analysis shows whether a 
product will break, wear out, or work the way it was designed. It is called analysis, but in the 
product development process, it is used to predict what is going to happen when the product is 
used.”). Computational Fluid Dynamics (CFD), SOLIDWORKS, http://www.solidworks.com/sw/
products/simulation/computational-fluid-dynamics.htm (last visited Nov. 30, 2015) (detailing 
computational fluid dynamics, which “simulates fluid (either liquid or gas) passing through or 
around an object. The analysis can be very complex—for example, containing in one calculation 
5
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functional applications of 3D modeling include providing an outlet for 
inventorship, producing a repaired version of a damaged object, and 
manufacturing items desired on an impulse.13 
CAD models can be produced in one of two ways: using 3D 
modeling software or using a 3D scanner. Three-dimensional modeling 
software varies from extremely complex, commercial programs, such as 
Autodesk’s 3ds Max, to basic, free options like Google’s SketchUp. 
While each software possesses a unique user-interface, on an elementary 
level, modeling is generally achieved through the use of principal, 
drawing, modification, construction, camera, and walkthrough tools for 
manipulation of a model in 3D space.14 Medical professionals regularly 
use 3D modeling software to teach medical students surgical procedures 
or to show a patient his or her potential “before and after” results prior to 
going under the knife. 
Three-dimensional scanning characteristically operates by 
triangulation of a laser over a stationary object.15 A laser band scans 
across the physical subject transfiguring it into a 3D digital file.16 A 
relatively novel and robust exercise of 3D scanning capabilities is 3D 
facial scanning, which is a critically useful tool for identification and 
verification of individuals employed for homeland security.17 
Three-dimensional printers work similarly to inkjet printers in that 
they utilize digital files to create a physical transformation of that file by 
depositing a selected medium layer-by-layer rather than drop-by-drop.18 
The layers are also blended together in order to create a physical object 
that appears cohesive and whole.19 Each layer can be seen as a thinly 
heat transfer, mixing, and unsteady and compressible flows. The ability to predict the impact of 
such flows on your product performance is time consuming and costly without some form of 
simulation tool.”). 
13. Almost Everything You Always Wanted to Know About 3D Scanning, supra note 12. 
14. SketchUp, Drawing quickly, TRIMBLE NAVIGATION LIMITED, http://help.sketchup.com/
en/article/115429 (last visited Nov. 15, 2015) (giving an overview of the tools drawing programs 
generally use: principal tools are tools that are used a lot to select and modify geometry; drawing 
tools are tools used to create geometry; modification tools are tools used to modify existing 
geometry; construction tools are tools used to create construction lines or points and document your 
model; camera tools are tools used to view geometry; and walkthrough tools are tools to explore 
your model).  
15. Anselmo Lastra, et al., 3D Scanning for Biometric Identification and Verification, 
INSTITUTE FOR HOMELAND SECURITY SOLUTIONS (2010), http://sites.duke.edu/ihss/files/
2011/12/IHSS_Research-Brief_Lastra.pdf.  
16. Id.
17. Id. 
18. John Patrick Pullen, You Asked: How Does 3-D Printing Work?, TIME (Jan. 16, 2015),
https://time.com/3671722/3d-printing/.  
19. Id. 
6
Akron Law Review, Vol. 49 [2015], Iss. 3, Art. 5
http://ideaexchange.uakron.edu/akronlawreview/vol49/iss3/5
2016] “TRANSPLANTING” ORGAN DONORS WITH PRINTERS 745 
sliced horizontal cross-section of the eventual object with an 
approximate layer thickness of 100 microns.20 To put that in perspective, 
a piece of printer paper is 100 microns thick.21 However, extremely high 
precision 3D printers exist, which can create layers as thin as 16 
microns.22 
B. 3D Printing Technologies and Methods 
There are various methods of 3D printing with each process adding 
layers generally by transferring multiple layers of a material onto a 
construction platform, starting with the bottom layer. Three main 
methods of 3D printing exist today, namely, selective laser sintering 
(SLS), fused deposition modeling (FDM), and stereolithography 
(SLA).23 
SLS employs a powerful laser to fuse tiny particles of metal, 
plastic, ceramic, or glass into a desired 3D shape.24 The laser 
discriminately combines the powdered material by scanning the cross-
sections generated by the 3D modeling program on the surface of the 
powder bed.25 Once all cross-sections are scanned, the powder bed is 
lowered by one layer thickness.26 Subsequently, a new layer of material 
is added on top of the prior layer, and the process is repeated until the 
object is completed.27 
FDM forms each layer of a 3D object by extruding metal or a 
20. Id. 
21. Lucas Mearian, The first 3D printed organ—a liver—is expected in 2014, COMPUTER 
WORLD (December 26, 2013 7:05 AM PT), http://www.computerworld.com/article/2486952/
emerging-technology/the-first-3d-printed-organ——a-liver——is-expected-in-2014.html. 
22. PolyJet, SOLID CONCEPTS, https://www.solidconcepts.com/technologies/polyjet/ (last
visited Nov. 30, 2015); see also MRSEC Education Group, Size and Scale, UNIVERSITY OF
WISCONSIN-MADISON (2015), http://education.mrsec.wisc.edu/36.htm (stating that “[a] micrometer, 
also called a micron, is one thousand times smaller than millimeter. It is equal to 1/1,000,000th (or 
one millionth of meter). Things on this scale usually can’t be seen with your eyes. The diameter of a 
hair, which is 40-50 microns wide, is very hard to discern without the use of a magnifying glass. A 
magnifying glass will help you see a dust mite. Dust mites are usually around 400 microns long.”). 
23. Mark Fleming, What is 3D Printing? An Overview, 3D PRINTER,
http://www.3dprinter.net/reference/what-is-3d-printing (noting that “Fused Deposition Modeling” 
and its abbreviation, FDM, are trademarked by Stratasys. The company RepRap uses a similar 
process but has called it “Fused Filament Fabrication” (FFF) so as to not interfere with Stratasys’s 
trademark.).  
24. 3D Printing.com, What is 3D printing?, GENESIS FRAMEWORK,
http://3dprinting.com/what-is-3d-printing/#whatitis (last visited Nov. 30, 2015).  
25. Id. 
26. Id.
27. Id.
7
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thermoplastic material through a heated nozzle onto a build platform.28 
The nozzle is capable of moving in both horizontal and vertical 
directions by a numerically controlled mechanism, directly controlled by 
a computer-aided manufacturing software package.29 Each layer hardens 
immediately after it is deposited and bonds to the previous layer to form 
the eventual object.30 
SLA, the original method of 3D printing, operates using a liquid 
ultraviolet curable photopolymer resin and an ultraviolet laser to build an 
object’s layers one by one.31 The ultraviolet laser beam is used to draw 
out the 3D model one layer at a time from the resin.32 To accomplish 
this, the laser beam traces a cross-section of the 3D model on the surface 
of the liquid resin.33 Exposure to the laser light cures and solidifies the 
tracing on the resin and fixes it to the layer below.34 Then, after the 
pattern descends by a distance equivalent to the thickness of one layer, a 
resin-filled blade glides across it, re-coating it with new liquid resin.35 
After the prior layer has been re-coated, the subsequent layer pattern is 
traced, joining the previous layer.36 
C. Applications of 3D Printing 
The applications of 3D printing are limitless. The robustness of 
today’s machines and surplus of material choices accommodate the 
imagination, inclusive of design visualization, prototyping, metal 
casting, architecture, healthcare, entertainment, and home use. Recent 
breakthroughs in 3D printing have been in the in the automotive, 
construction, biomedical, and biotechnology industries. 
The automotive industry is taking full advantage of the seemingly 
endless capabilities of 3D printing. Local Motors, an American 
company, printed the first working, electric car at a trade show in 
28. Id.
29. Id.; see also Clive Ferguson, A History of Numerically Controlled Machine Tools, 
ACADEMIA (1978), 
http://www.academia.edu/670021/A_history_of_numerically_controlled_machine_tools (defining 
numerical control as “the dimensional and sequential operation of a machine tool by means of coded 
numeric information . . . the information is used to cause, at the appropriate time, the movement of 
the part or parts being machined and for the tool or tools involved together with, in some cases, 
selection of correct speeds, feed rates, etc.”).  
30. What is 3D Printing?, supra note 24. 
31. Id. 
32. Id. 
33. Id. 
34. Id. 
35. Id. 
36. Id. 
8
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Chicago.37 It was completed in just two days and is comprised of only 
49 carbon fiber and plastic parts.38 Additionally, Kevin Czinger, the 
Founder and CEO of Divergent Microfactories, Inc., built the first 3D 
printed supercar, called “Blade.”39 The supercar is composed completely 
of 3D printed aluminum nodes and carbon fiber connectors, and it 
weighs significantly less than one ton, can pump out as much as 700 
horsepower, and can accelerate from zero to 60 in a little more than two 
seconds.40 Blade demonstrates 3D printing’s ability to produce products 
that can stand up to extreme forces and performance.41 
Audi and Kia are also taking advantage of this progressive 
technology.42 While it has not been unusual for automotive companies to 
utilize 3D printed parts in prototypes, Audi and Kia are forerunners in 
taking it to the next step.43 Both automotive companies are working 
toward including 3D printed parts within production vehicles. Audi is in 
the process of streamlining how its 3D printing techniques and 
automotive production methods work together so that it can use metal 
3D printed parts in actual production, while Kia has introduced 3D 
printed parts into a concept car for presentation at the North American 
International Auto Show (NAIAS).44 
In construction, Amsterdam’s Dus Architects is revolutionizing the 
industry by erecting the first 3D printed house.45 While the process will 
take a total of three years, it will be compiled of 13 rooms made of 
interlocking plastic parts.46 The 3D printing of homes will produce great 
benefits: zero waste, reduced costs, and completely recyclable parts.47 
37. Tracey Kirkland, 3D-printing: American company Local Motors releases world’s first
computer printed car, ABC (October 13, 2014 10:17 AM), http://www.abc.net.au/news/2014-10-
13/american-company-makes-worlds-first-3d-printed-car/5810234.  
38. Id. 
39. Eddie Krassenstein, World’s First 3D Printed Supercar is Unveiled, 3D PRINT.COM (June 
24, 2015), http://3dprint.com/74810/3d-printed-supercar-blade/. 
40. Id. 
41. See generally id. 
42. Michael Molitch-Hou, Kia Concept SUV Features 3D Printed Parts, 3D Printing
Industry, (January 11, 2016), http://3dprintingindustry.com/2016/01/11/64658/; Tyler Koslow, Audi 
Looks to Put 3D Printed Metal End Parts into Their Autos, 3D PRINTING INDUSTRY (November 13, 
2015), http://3dprintingindustry.com/2015/11/13/audi-looks-to-put-3d-printed-metal-end-parts-into-
their-autos/. 
43. Id. 
44. Id. 
45. Tom McKay, Major Breakthrough in 3-D Printing Could End One of the World’s 
Biggest Issues, MIC NETWORK (Apr. 7, 2014), http://mic.com/articles/87085/major-breakthrough-
in-3-d-printing-could-end-one-of-the-world-s-biggest-issues. 
46. Id. 
47. Id. 
9
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This use could also lead to the 3D printing of low-cost temporary 
housing for homeless and use of biodegradable materials for festivals.48 
Yale and Oxford Performance Materials (OPM) are collaborating to 
benefit biomedical applications that employ 3D printing.49 Using OPM’s 
high performance polyetherketoneketone (PEKK) polymer, the planned 
venture includes ten projects comprising a 3D printed PEKK prosthesis 
for rib replacement and 3D printed PEKK devices that deliver 
therapeutics for improved vertebral fusion.50 
One of the most innovative and progressive areas of 3D printing is 
in biotechnology for tissue engineering applications, which has been 
referred to as 3D bioprinting, organ printing, or computer-aided tissue 
engineering.51 The latest advances in 3D printing have allowed for the 
manufacture of intricate, functional, living tissue from biocompatible 
materials, cells, and supporting components.52 This application of 3D 
printing has been useful for regenerative medicine and addressing the 
lack of available tissues and organs for transplantation.53 
D. 3D Bioprinting Tissue Engineering 
Although 3D printing has long been a tool to generate 
biotechnology devices, the present focus of many researchers has been 
on printing cells to form functional tissues.54 The goal of 3D bioprinting, 
which has evolved from the amalgamation of early stereolithographic 
techniques and breakthroughs in biology, is to produce tissues and 
organs suitable for laboratory investigation, disease modeling, and 
therapeutics.55 With large research universities and companies backing 
this technology, it is probable that 3D bioprinting will eventually 
become one of the principal areas of research and investment in the 
upcoming years.56 
48. Id. 
49. Bridget Butler Millsaps, Yale University and OPM Collaborate on Ten 3D Printing
Projects to Further Biomedical Applications, 3DPRINT.COM (Oct. 29, 2014), 
http://3dprint.com/21912/yale-university-opm-3d-print/. 
50. Id. Biomedical Raw Materials, OXFORD PERFORMANCE MATERIALS,
http://www.oxfordpm.com/biomedical_raw_materials.php (last visited Nov. 30, 2015) (defining 
PEKK as a biocompatible, thermoplastic polymer used for implantable medical devices). 
51. Murphy & Atala, supra note 1.
52. Id. 
53. Id.
54. Suraj Kannan, The 3D Bioprinting Revolution, HARVARD SCIENCE REVIEW (May 1,
2014), http://harvardsciencereview.com/2014/05/01/the-3d-bioprinting-revolution/. 
55. Id. 
56. Id. (identifying Harvard University and Organovo as large supporters of 3D bioprinting).
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Three-dimensional bioprinting presents additional challenges not 
seen in non-biological 3D printing applications, including choice of 
biocompatible materials, cell types, cell growth and differentiation 
factors, and the fragilities associated with living cells and manufactured 
tissue.57 With the help of technologies from the areas of engineering, 
biomaterials, cellular biology, physics, and medicine to address those 
intricacies, 3D bioprinting has already produced some promising results 
such as the generation and transplantation of multilayered skin, bone, 
vascular grafts, heart tissue, and cartilage.58 Other relevant uses include 
developing high-throughput 3D bioprinted tissue models for research, 
drug discovery, and toxicology.59 
E. Traditional Tissue Engineering Versus Bioprinting 
The National Institute of Biomedical Imaging and Bioengineering 
has defined tissue engineering as the “practice of combining scaffolds, 
cells, and biologically active molecules into functional tissues.”60 Tissue 
engineering aims to assemble functional constructs that repair, preserve, 
or improve damaged tissues or entire organs.61 Traditional tissue 
engineering generally follows a top-down approach where cells are 
seeded on a scaffold.62 Despite the fact that this method has resulted in 
some of the earliest clinical successes of tissue engineering, it does not 
permit sufficient temporal and spatial control of cells and growth factors 
seeded in the scaffold.63 With this constraint, synthesized tissues in 
traditional tissue engineering have a limit to their complexity.64 
Three-dimensional bioprinting employs a customized bottom-up 
approach where discrete components of the tissue are arranged in such a 
fashion to permit formation of compound tissue construction.65 This is 
made possible by CAD, which allows for careful placement of cells, 
materials, and morphogens to duplicate the varieties of organization 
57. Murphy & Atala, supra note 1. 
58. Id. 
59. Id.
60. National Institute of Biomedical Imaging and Bioengineering, Tissue Engineering and
Regenerative Medicine, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES, 
http://www.nibib.nih.gov/science-education/science-topics/tissue-engineering-and-regenerative-
medicine (last visited Nov. 30, 2015).  
61. Id.
62. Kannan, supra note 54. 
63. Id.
64. Id. 
65. Id. 
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found in the body.66 These strategies usually rely on cells’ innate self-
assembly and growth factor-driven mechanisms to create the functional 
biomimetic tissues.67 
F. Methods and Parameters of 3D Bioprinting 
There are two different types of bioprinting methods. These include 
extrusion printing (contact) and thermal ink-jet printing (contactless).68 
In extrusion printing, which is the most common method of 3D 
bioprinting, filaments are pushed through a nozzle to generate a 3D 
structure.69 Therefore, there is contact between the delivery apparatus 
and the “bio-ink.”70 In thermal ink-jet printing, small ink bubbles are 
produced by pulsing current through the heating component of the 
printhead.71 Subsequently, the change in pressure collapses the ink 
bubbles and expels the ink from the nozzle.72 Hence, there is no contact 
between the delivery apparatus and the bio-ink.73 
Compared to conventional 3D printing, 3D bioprinting involves 
greater complexities. It is vital to take into account several parameters 
with the development of 3D bioprinting, such as the resolution of the 
printing, material selection (bio-ink), and cell variability.74 Deciding 
which 3D printer to utilize centers on what the desired resolution is.75 
Designing tissues involves macro and micro-scale control; thus, several 
methods must be employed to produce both the gross architecture and 
66. Id. 
67. Id.; see also Raphaël Devillard et al., Cell patterning by laser-assisted bioprinting, 
METHODS IN CELL BIOLOGY, 2014, at 119, 159-74, available at http://www.ncbi.nih.gov/
pubmed/24439284.  
68. Kannan, supra note 54. 
69. Id.; see also Cameron J. Ferris et al., Biofabrication: an overview of the approaches used
for printing of living cells, APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2013, at 4243—58, 
available at https://www.ro.uow.edu.au/cgi/viewcontent.cgi?article=1580&context=smhpapers. 
70. Kannan, supra note 54; Dan Ferber, An Essential Step Toward Printing Living Tissues, 
Harvard John A. Paulson School of Engineering and Applied Sciences (February 19, 2014), 
https://www.seas.harvard.edu/news/2014/02/essential-step-toward-printing-living-tissues (defining 
“bio-ink” as “functional inks with useful biological properties” or “tissue-friendly inks containing 
key ingredients of living tissues”). 
71. Kannan, supra note 54; see also Xiaofeng Cui et al., Thermal Inkjet Printing in Tissue
Engineering and Regenerative Medicine, RECENT PATENTS ON DRUG DELIVERY AND
FORMULATION, 2012, at 149-55, available at https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3565591. 
72. Kannan, supra note 54. 
73. Id. 
74. Id. 
75. Id.
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detailed patterning of cells.76 Similarly, the selection of bio-ink is 
critical.77 Research and development of new bio-inks has been a high 
priority, including hydrogel mixtures and water-based inks.78 
G. Early Successes in Bioprinting 
Several research groups have already achieved success with 
manufacturing functional tissues, including skin, blood vessels, 
cartilage, the bladder, and the uterus.79 For instance, researchers at the 
Scripps Research Institute were able to produce artificial cartilage 
comprised of human chondrocytes in a hydrogel.80 Additionally, 
scientists at Cornell University have constructed aortic valve conduits 
composed of various cell types and patterned cell distribution.81 
However, these early achievements did not prevail without 
challenges. Although these advances have demonstrated how much 
potential 3D bioprinting holds, this technology is limited by the same 
obstacle as alternative tissue engineering methods: vascularization.82 
Blood vessels are vital for transferring nutrients, oxygen, and wastes 
throughout thick tissues; without them cell death is inevitable.83 Without 
vascularization, tissues produced by 3D printing are required to be very 
thin, a limitation that has until now barred the creation of larger tissues 
and organs.84 
H. Current Ventures in Bioprinting 
In February of 2014, the Lewis Lab at the Harvard School of 
Engineering and Applied Sciences made an astounding discovery.85 The 
76. Id. 
77. Id. 
78. Id. 
79. Kate Lyons, Humans could be fitted with kidneys made on 3D PRINTERS thanks to
Australian researchers who have already grown miniature organs in labs, ASSOCIATED 
NEWSPAPERS, (May 23, 2014 2:08 PM EST), http://www.dailymail.co.uk/sciencetech/article-
2637158/Humans-fitted-kidneys-3D-printers.html.  
80. Kannan, supra note 54; see also About The Scripps Research Institute, THE SCRIPPS 
RESEARCH INSTITUTE, (2015), http://www.scripps.edu/about/index.html (stating that the Scripps 
Research Institute is a private, nonprofit medical research facility located in California, dedicated to 
research and education in biomedical sciences).  
81. Kannan, supra note 54; see also Bin Duan et al., 3D Bioprinting of Heterogeneous Aortic
Valve Conduits with Alginate/Gelatin Hydrogels, J. BIOMED MATER RES A, 2013, at 1255-64, 
available at https://ncbi.nlm.nih.gov/pmc/articles/PMC3694360. 
82. Kannan, supra note 54. 
83. Id. 
84. Id. 
85. Id. 
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group used a customized inkhead bioprinter and inventive bio-inks, such 
as a gelatin-based ink for the scaffold and two cell-containing inks.86 
Notably, the seemingly most novel portion of the investigation was the 
use of a Pluronic-based bio-ink that switches from a solid to a liquid 
when cooled below 4o C.87 Accordingly, the lab was able to produce 3D 
constructs with an intricate grid of Pluronic ink, which upon cooling 
resulted in liquidification of the Pluronic and creation of channels within 
the structure.88 To convert these channels into vasculature, they were 
subsequently endothelialized.89 The Lewis group used this Pluronic ink 
technique to print a construct of human umbilical vein cells, neonatal 
dermal fibroblasts, and vasculature.90 Down the line, a bioreactor could 
be utilized for perfusion to allow for nutrient and oxygen flow within the 
structure.91 
Organovo, a San Diego-based company, has also begun conquering 
the vasculature hurdle.92 The company stated that it had overcome 
vascularization to a degree in its endeavor to print the first functional 
liver.93 They were able to produce liver tissue with a thickness of greater 
than 500 microns that could remain in a fully functional state for at least 
40 days.94 In order to create a working liver, various cell types with 
different functions must be combined.95 Among the cell types Organovo 
utilized were fibroblasts and endothelial cells.96 These are important 
players for developing a vasculature network, which allowed the 
company to print thick tissue with good cell variability.97 
In the future, the production of a fully-operative liver will be a 
landmark in 3D bioprinting history because it will prove that 3D printed 
tissue is capable of living long enough to test drug efficacy or to be 
86. Id.; see also David B. Kolesky et al., 3D Bioprinting of Vascularized, Heterogeneous
Cell-Laden Tissue Constructs, Advanced Materials, May 21, 2014, at 3124-30, available at 
https://www.onlinelibrary.wiley.com/doi/10.1002/adma.201305506/abstract. 
87. Kannan, supra note 54. 
88. Id. 
89. Id. 
90. Id. 
91. Id. 
92. Mearian, supra note 21. 
93. Id. 
94. Id. 
95. Id. (describing the cell types making up a human liver. These include Kupffer cells for
removing debris from the blood, stellate cells for regenerating tissue that has died or been injured, 
and sinusoidal endothelial cells, which make up the interior surface of blood vessels and lymphatic 
vessels.).  
96. Id. 
97. Id. 
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implanted into the body where it can mature.98 
I. The Incentivization of 3D Bioprinting 
There is no doubt that the general field of 3D printing is booming. 
With the influx of new developments and uses of the technology, 
analysts at International Data Corporation, an American market research 
firm that specializes in information and consumer technology, forecasted 
that worldwide spending on 3D printing would total a mere $2.7 billion 
in 2014.99 However, they expect long-term growth of 29% a year, which 
is much greater than the normal trends in manufacturing.100 Hopeful 
analysts at Morgan Stanley predict even faster annual growth of 34%, 
which amounts to more than $20 billion in sales by 2020.101 
Funding for whole organ regeneration research is currently less 
than $500 million a year in the U.S., while cancer research and 
HIV/AIDS research receive $5 billion and $2.8 billion, respectively.102 
While regenerative medicine is seen as the future of healthcare, the field 
is presently falling through the cracks.103 In order to fuel the 
development of bioprinted organs, the Methuselah Foundation, a 
Virginia-based nonprofit that backs regenerative medicine research, 
announced a $1 million prize for the first organization to print a fully 
functioning liver.104 Additionally, the foundation has begun a campaign 
to finance research at major research institutions using Organovo’s 
patented NovoGen Bioprinting technology.105  
III. THE EVOLUTION OF ORGAN DONOR LAW
Since as early as the 1800s, organ donation has been in existence.106 
98. Id. 
99. George Anders, HP’s 3D Print Breakthrough Could Push Rivals ‘Out of Business’, 
FORBES (Oct.29, 2014 9:30 AM), http://www.forbes.com/sites/georgeanders/2014/10/29/hps-3d-
print-breakthrough-could-push-rivals-out-of-business/. 
100.  Id.  
101.  Id. 
102.  Mearian, supra note 21. 
103.  Id. 
104.  Id. 
105.  PRNewswire, Organovo and Methuselah Foundation Announce Funding of Bioprinting 
Research at Research Institutions, ORGANOVO (Jul. 24, 2013), http://ir.organovo.com/news/press-
releases/press-releases-details/2013/Organovo-and-Methuselah-Foundation-Announce-Funding-of-
Bioprinting-Research-at-Research-Institutions/.  
 106.  Timeline of Historical Events Significant Milestones in Organ Donation and 
Transplantation, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES,
http://www.organdonor.gov/legislation/timeline.html (last visited Dec. 2, 2015). 
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In 1869, the first skin transplant was performed. With such a sensitive 
exchange, it was foreseeable that in due time laws would be put into 
place to regulate this activity. However, it took over a century for the 
government to enact federal law to control organ donation and 
transplantation. In 1968, the first organ procurement organization, the 
New England Organ Bank, was formed.107 In that same year, the 
National Conference of Commissioners on Uniform State Laws drafted 
the Uniform Anatomical Gift Act, which established the Uniform Donor 
Card as a legal document of gift in all 50 states, identified the types and 
priority of individuals who could donate a deceased person’s organs, and 
enabled anyone over 18 years old to legally donate his or her organs 
upon death.108 The biggest breakthrough in organ donor law came in 
1984, when Congress passed NOTA. 
This Note now explores how organ donation has evolved 
throughout the decades by way of Congress and in the eyes of the 
general public. Part III.A discusses the National Organ Transplant Act, 
which is still in effect today and outlawed the selling of human organs 
and established the OPTN and Scientific Registry of Transplanted 
Recipients.109 It also provided for grants for the establishment, initial 
operation, and expansion of organ procurement organizations. This Part 
next discusses the Organ Donation and Recovery Improvement Act, 
which expanded the authority of NOTA. Part III.B presents the different 
arguments for and against live donor organ sales that the American Bar 
Association has presented. This Part explains that these arguments are 
applicable to 3D printed organ sales because the technology is intended 
to serve the same purpose—to expedite the distribution of organs for 
transplantation. 
A. Federal Law: National Organ Transplant Act: Section 301 (C.F.R. 42 
U.S. Code § 274e) 
The field of organ donation and transplantation is one of the most 
 107.  Organ Procurement Organizations, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES, 
http://organdonor.gov/materialsresources/materialsopolist.html (last visited Dec. 2, 2015) (stating 
that Organ Procurement Organizations are nonprofit organizations that are “responsible for two 
main functions within their designated service area: 1) increasing the number of registered donors, 
and 2) coordinating the donation process when actual donors become available”).  
108.  Id. 
 109.  Id. (explaining that the Organ Procurement and Transplantation Network was created to 
ensure fair and equitable allocation of donated organs and the Scientific Registry of Transplanted 
Recipients was implemented to conduct an ongoing evaluation of the scientific and clinical status of 
an organ transplantation.).  
16
Akron Law Review, Vol. 49 [2015], Iss. 3, Art. 5
http://ideaexchange.uakron.edu/akronlawreview/vol49/iss3/5
2016] “TRANSPLANTING” ORGAN DONORS WITH PRINTERS 755 
regulated areas of healthcare today.110 Both state and federal statutes 
have been enacted to attempt to provide the safest and most evenhanded 
system for distribution and transplantation of donated organs.111 
As stated above, in 1984 Congress enacted NOTA. This act created 
the OPTN, which is run by the United Network for Organ Sharing 
(UNOS), a private, non-profit organization under federal contract.112 
Federal regulations promulgated pursuant to NOTA provide a regulatory 
framework for the structure and operation of the OPTN where it is 
responsible for increasing and ensuring the effectiveness, efficiency, and 
equity of organ sharing in the national system of organ allocation and for 
increasing the supply of donated organs for transplantation.113 Section 
301 of NOTA prohibits the purchase of organs under subsection (a), 
stating that “it shall be unlawful for any person to knowingly acquire, 
receive or otherwise transfer any human organ for valuable 
consideration for use in human transplantation if the transfer affects 
interstate commerce.”114 Further, under subsection (b) “[a] violator of 
this law shall be fined not more than $50,000 or imprisoned not more 
than five years, or both.”115 
NOTA explicitly defines the terms “human organ,” “valuable 
consideration,” and “interstate commerce.”116 According to the original 
Section 301 of the 1984 version of NOTA, “human organ” in Subsection 
(c)(1) was defined as the “human kidney, liver, heart, lung, pancreas, 
bone marrow, cornea, eye, bone, and skin, and any other human organ 
specified by the Secretary of Health and Human Services (HHS) by 
regulation.”117 However, Section 301 has been amended several times 
since its enactment.118 In 1988, Congress broadened the definition by 
inserting “any subpart thereof” after the listed organs and expanding the 
definition of “human” to include fetuses.119 Another amendment in 
2007, crafted a new definition of “human organ,” which states, “the term 
110.  Legislation and Policy, supra note 6. 
111.  Id.  
112.  Id. 
113.  Id. 
114.  National Organ Transplant Act, 42 U.S.C § 274 (1984).  
115.  Id. 
116.  Id. 
117.  Id. 
118.  Lingyun Kao, Flynn v. Holder, a Narrow Interpretation of National Organ Transplant 
Act (NOTA) Reached Positive Policy Effects, THE UNIVERSITY OF HOUSTON LAW CENTER, 3 
(2013), http://www.law.uh.edu/healthlaw/perspectives/2013/
Kao_Flynn%20v.%20Holder,%20a%20Narrow%20Interpretation%20of%20National%20Organ%2
0Transplant%20Act%20(NOTA)%20Reached.pdf. 
119.  Id. 
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‘human organ’ means the human (including fetal) kidney, liver, heart, 
lung, pancreas, bone marrow, cornea, eye bone, skin and intestine, 
including the esophagus, stomach, small and/or large intestine, or any 
portion of the gastrointestinal tract.”120 
However, the Secretary of HHS has since expanded the definition 
of human organs by adding vascularized composite allografts to the 
covered list of human organs under the OPTN final rule.121 
Subsection (c)(2) of Section 301 does not define “valuable 
consideration” in terms of what it is, but rather what it is not. The term 
“valuable consideration” under the statute “does not include the 
reasonable payments associated with the removal, transportation, 
implantation, processing, preservation, quality control, and storage of a 
human organ or the expenses of travel, housing and lost wages incurred 
by the donor of a human organ in connection with the donation of the 
organ.”122 However, it has been recognized that “the title of a statute or 
 120.  Public Health Service, Department of Health and Human Services Organ Procurement 
and Transplantation Network, 42 C.F.R. § 121.13 (2015).  
 121.  Id.; see also Final Rule, OFFICE OF THE FEDERAL REGISTER (2013), 
https://www.federalregister.gov/articles/text/raw_text/201/315/731.txt (discussing that a final rule 
issued by HHS was responsible for the addition of vascularized composite allografts; the rule went 
into effect on July 3, 2014. “The transplant community has referred to the transplants of intact 
vascularized body parts such as hands and faces as composite tissue allograft transplants. As tissues, 
these components have been under the regulatory jurisdiction of the Food and Drug Administration 
(FDA). For the reasons outlined in the NPRM, the Secretary believes that these components, based 
on their clinical characteristics, are more characteristic of organs as defined specifically in NOTA 
and subsequently by regulation in the case of intestines and blood vessels used in conjunction with 
organ transplantation. For the purpose of this regulation, these components are described as 
vascularized composite allografts (VCAs) . . . . Pursuant to this rule, for a body part to be defined as 
a VCA, it must have all the following characteristics: A body part that is (1) Vascularized and 
requires blood flow by surgical connection of blood vessels to function after transplantation; (2) 
containing multiple tissue types; (3) recovered from a human donor as an anatomical/structural unit; 
(4) transplanted into a human recipient as an anatomical/structural unit; (5) minimally manipulated 
(i.e., processing that does not alter the original relevant characteristics of the organ relating to the 
organ’s utility for reconstruction, repair, or replacement—examples of minimal manipulation 
include cutting, grinding, and shaping of a VCA); (6) for homologous use (i.e., the replacement or 
supplementation of a recipient’s organ with an organ that performs the same basic function or 
functions in the recipient as in the donor, e.g., a hand from the donor is to be used as a hand in the 
recipient); (7) not combined with another article such as a device; (8) susceptible to ischemia and, 
therefore, only stored temporarily (e.g., cold storage in preservation medium and intended for 
implantation into a recipient within hours of the recovery) and not cryopreserved; and (9) 
susceptible to allograft rejection, generally requiring immunosuppression that may increase 
infectious disease risk to the recipient.”).  
 122.  National Organ Transplant Act, 42 U.S.C § 274 (1984); see also Change to the Definition 
of “Human Organ” Under Section 301 of the National Organ Transplant Act of 1984, OFFICE OF
THE FEDERAL REGISTER (2013), https://www.federalregister.gov/articles/2013/10/02/2013-
24094/change-to-the-definition-of-human-organ-under-section-301-of-the-national-organ-
transplant-act-of (asserting that Congress’s amendment to Section 301 in 2007 also affected 
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section can aid in resolving ambiguity in the legislation’s text.”123 
Section 301 is titled “Prohibition of Organ Purchases,” which does not 
explicitly mention “valuable consideration.”124 Thus, Professor Kevin 
Marshall suggests that reading Section 301’s text in light of its title 
implies that the indistinct phrase “valuable consideration” addresses 
organ transfers “that could be considered to involve a ‘purchase,’ rather 
than all donations that may involve some exchange.”125 
Subsection (c)(3) of Section 301 defines the term “interstate 
commerce.” However, it is defined as prescribed by section 201(b) of 
the Federal Food, Drug, and Cosmetic Act.126 The Food, Drug, and 
Cosmetic Act defines “interstate commerce” as “(1) commerce between 
any State or Territory and any place outside thereof, and (2) commerce 
within the District of Columbia or within any other Territory not 
organized with a legislative body.”127 This subsection of NOTA has 
never been amended. 
State law also prohibits the sale of organs in compliance with the 
Uniform Anatomical Gift Act (UAGA).128 The initial version of the 
UAGA failed to expressly mention commerce in organs.129 UAGA was 
amended in 1987 to bar unambiguously the purchase and sale of organs 
removed after death.130 Although this prohibition does not cover living 
donor organ purchases and sales, some states have tailored the 1987 
UAGA to include such a provision.131 
B. Arguments for and Against Living Donor Organ Sales 
What may be a precursor to 3D bioprinted organ sales is live donor 
organ sales. The American Bar Association has presented different 
arguments for and against live donor organ sales. These arguments are 
applicable to 3D printed organ sales because the technology is intended 
Subsection (C)(2) by excluding paired donation from the definition of “valuable consideration”). 
 123.  INS v. Nat’l Ctr. for Immigrants’ Rights, 502 U.S. 183, 189 (1991); see also C. Kevin 
Marshall, Legality of Alternative Organ Donation Practices Under § 274e, MEMORANDUM OPINION
FOR THE GENERAL COUNSEL DEPARTMENT OF HEALTH AND HUMAN Services, 41-2 (2007), 
http://www.justice.gov/sites/default/files/olc/opinions/attachments/2015/05/29/op-olc-v031-
p0040.pdf (concluding that in statutory text, “employment” referred to “unauthorized employment,” 
in accordance with the heading of § 274e). 
124.  Marshall, supra note 123. 
125.  Id. 
126.  42 U.S.C § 274. 
127.  Federal Food, Drug, and Cosmetic Act § 201, 21 U.S.C. § 321 (2015).  
128.  Shapiro, supra note 9. 
129.  Id.  
130.  Id. 
131.  Id.  
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to serve the same purpose—to expedite the distribution of organs for 
transplantation. However, because 3D bioprinted organs eliminate the 
live donor aspect, it strengthens or weakens any arguments involving the 
living donor. 
1. Arguments Supporting Live Donor Organ Sales
The weightiest argument in support of live donor organ sales is that 
authorizing human organ sales would produce a greater supply of rare 
and life-saving resources.132 Economists’ assertion that barring 
compensation for organs lessens supply is strengthened by years of 
reports of people’s offers to sell their organs.133 Thirty years ago during 
the NOTA hearings, one man submitted a letter to the U.S. House of 
Representatives Subcommittee on Health and the Environment in hopes 
of being compensated for his kidney to fund an education.134 In another 
letter, a mother wanted to sell an organ to pay for her daughter’s medical 
treatment135 
Another argument is that people should be able to do with their own 
body parts whatever they wish.136 Just as police officers, fishermen such 
as in “Deadliest Catch,” and steel workers are paid for their dangerous 
work, those who selflessly decide to assume the risk to give their organs 
to others should also be compensated.137 Indeed, some contend that 
because hospitals, doctors, laboratories, and pharmaceutical companies 
charge patients for transplantation-related products and services, it is 
unfair for donors not to be compensated.138 
Bolstering each of these arguments is that despite the fact that 
transplantation using paid living donors is unlawful, it occurs. Because 
of this, it might be better to legalize the practice so that it could be 
regulated properly.139 
2. Arguments Against Live Donor Organ Sales
There are five main objections to permitting live donor organ sales. 
First is that the organ buyer-seller relationship would be exploitative and 
132.  Id. 
133.  Id. 
134.  Id. 
135.  Id. 
136.  Id. 
137.  Id. 
138.  Id. 
139.  Id. 
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either cause or amount to an improper commodification of the body.140 
However, in rebuttal to this argument, society allows other exploitative 
practices, such as poorly paid labor practices, so why should organ sales 
be considered any more morally problematic?141 
Second is that paid organ donation could exclude disadvantaged 
people who cannot afford to pay for an organ.142 A counter to this 
argument is that the government or a privately run organization under 
governmental control could purchase the organs and then allocate them 
in a fair and equitable way.143 This would allow for compensation to the 
donor as well as a carefully regulated system to ensure impartial 
distribution. 
Third is that live organ donor sales would undercut voluntary organ 
donation.144 There is evidence showing that marketing in human organs 
would ultimately destroy people’s present willingness to donate their 
organs out of altruism, thereby decreasing the supply of organs.145 For 
example, when blood was first permitted for sale, the overall blood 
supply dropped sharply because the decrease in voluntary donations was 
larger than the increase in paid donations.146 However, it is possible for 
analogous compensated and charitable situations to coexist, such as 
professional social work and charitable social work.147 
Fourth, incentivizing organ donation through compensation would 
undermine the autonomy of true donation because of money’s 
manipulative and coercive impact.148 As mentioned above, organ market 
supporters have indicated that it is not unusual for society to allow 
people to undertake risks for money when they engage in hazardous 
occupations such as mining and jockeying.149 Additionally, people who 
donate an organ to a family member may be subject to a higher degree of 
coercion than those who sell their organs because of internal pressure 
from family members to save a loved one.150 
Finally, payment for organs would place an additional burden on 
the organ-recipient by greatly increasing the overall cost of 
140.  Id. 
141.  Id. 
142.  Id. 
143.  Id. 
144.  Id. 
145.  Id. 
146.  Id.  
147.  Id. 
148.  Id. 
149.  Id. 
150.  Id. 
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transplantation.151 However, compensation-supporters have argued that 
the scarcity of transplantable organs boosts the economic returns 
currently produced by transplant programs, and consequently, the 
financial incentives for donation would dwindle the overall costs of 
transplant procedures.152 
IV. APPLICABILITY OF EXISTING DONOR LAW TO 3D BIOPRINTING
Three-dimensional bioprinting will eventually supply a technology 
capable of expediting the organ donor process for waiting list candidates 
in dire need of organ transplantation. However, this technology may 
present an opportunity for capitalistic minds to exploit that desperation. 
Once organs are produced with great certainty of viability and little 
expectation of biological rejection, startups could assemble and begin 
manufacturing their own organs. While the OPTN is responsible for 
effectively distributing and handling donated transplanted organs, this 
new technology would override the OPTN-middleman. Taking that into 
account, there would be little to stop privately owned companies from 
producing their own organs and selling them directly to patients awaiting 
transplants. 
This Note now turns to the critical questions regarding applicability 
of NOTA for 3D bioprinting. Part IV.A analyzes whether organs 
produced through 3D bioprinting will be considered “human organs” 
and subject to regulation under NOTA and concludes that NOTA will be 
applicable to bioprinted organs. Part IV.B examines what types of 
consideration received in exchange for a bioprinted organ would be 
considered “valuable consideration” under NOTA and concludes that 
compensation of any kind will violate NOTA’s prescription against 
receipt of “valuable consideration” in exchange for human organs. Part 
IV.C discusses the term “interstate commerce” under NOTA, concluding
that an attempt to sell human organs within the United States, even 
human organs harvested outside of the United States, affects interstate 
commerce. Part IV.D explains whether 3D bioprinted organs would 
constitute “experimental treatment” and thus, whether waiting list 
candidates could promptly receive manufactured organs or be required 
to wait until after the FDA approval process. It concludes that similar to 
in-vitro organogensis, 3D bioprinted organs will have to undergo FDA 
testing and approval, delaying any immediate promise of organ 
transplantation to waiting list candidates. Finally, Part IV.E explores 
151.  Id. 
152.  Id. 
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current organ trafficking and the great potential for black market 
operations of bioprinted organs, concluding that by Congress amending 
NOTA, it could either assert more control over or avoid such operations. 
Because this is a technology that should come to fruition in the near 
future, applicable case law is nonexistent. However, there is common 
law exploring generally what may fall under the definitions within 
Section 301. This precedent can be used to help forecast what problems 
may arise with respect to 3D bioprinting. Also explored is whether 3D 
bioprinted organs would be perceived as a readily useable human organ 
or as an “experimental drug.” The promise of solving the donor problem 
would be halted if, like in vitro grown organs, printed organs must 
undergo clinical testing. 
A. Interpreting Section 301 of NOTA: What Qualifies as a “Human 
Organ?” 
While Section 301 lists an expanse of “human organs,” there is 
little case law interpreting this lexicon. In Flynn v. Holder, the Ninth 
Circuit held that the definition of “bone marrow,” which is included 
under NOTA’s definition of “human organ,” did not encompass 
peripheral blood stem cells obtained through apheresis but only actual 
bone marrow extracted by aspiration.153 In Flynn, the plaintiffs 
challenged the constitutionality of NOTA’s ban on compensation for 
bone marrow transplants.154 The Ninth Circuit based its decision wholly 
on “statutory interpretation of NOTA, not the plaintiffs’ allegation that 
NOTA’s prohibition on selling bone marrow violated the Equal 
Protection Clause of the U.S. Constitution, which prohibits the federal 
and state governments from denying any person the equal protection of 
the law.”155 The court reasoned that because NOTA does not ban blood 
 153.  Flynn v. Holder, 684 F.3d 852, 855 (9th Cir. 2012). Donating peripheral blood stem 
cells, NATIONAL MARROW DONOR PROGRAM, http://bethematch.org/support-the-cause/donate-
bone-marrow/donation-process/donating-pbsc/ (last visited Dec. 2, 2015) (“Peripheral blood stem 
cell (PBSC) donation is one of two methods of collecting blood-forming cells for bone marrow 
transplants. The same blood-forming cells that are found in bone marrow are also found in the 
circulating (peripheral) blood. PBSC donation is a nonsurgical procedure, called apheresis. The 
donation takes place at an experienced blood center or outpatient hospital facility.”). Bone Marrow 
Aspiration and Biopsy, CANCER.NET, http://www.cancer.net/navigating-cancer-care/diagnosing-
cancer/tests-and-procedures/bone-marrow-aspiration-and-biopsy (last visited Dec 2, 2015) (“Bone 
marrow aspiration and bone marrow biopsy are short medical procedures that collect a sample of 
bone marrow, the spongy tissue inside of bones, so it can be examined. The procedures, which are 
often done together, are used to diagnose some cancers, provide specific information about a blood 
cancer, or monitor the side effects and effectiveness of chemotherapy.”). 
154.  Flynn, 684 F.3d at 852. 
155.  Id. at 865. Glenn Cohen, Selling Bone Marrow—Flynn v. Holder, THE NEW ENGLAND
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donations and peripheral blood stem cell apheresis donation is 
essentially the same as a blood donation, it was permissive.156 
The Flynn court concluded that Congress could not have had the 
intent to address the apheresis method when it passed NOTA because 
the method did not exist at the time. Statutory interpretation was 
necessary in order to clarify the meaning of “bone marrow.” Flynn v. 
Holder narrowed the meaning of “bone marrow” in NOTA to include 
bone marrow obtained only directly, meaning through the aspiration 
method. Therefore, if bone marrow is printed directly from a 3D 
bioprinter (analogous to the aspiration method), it will likely fall under 
the definition of “human organ” of Section 301. However, if a 3D 
bioprinter were to use peripheral blood stem cells and subsequently 
transform the cells into bone marrow that would seem to circumvent the 
meaning of “bone marrow” in the statute in the same way peripheral 
blood stem cell apheresis does. 
There are institutions currently producing lab-grown organs. 
Anthony Atala of Wake Forest has drawn international commendation 
for being the first scientist to implant lab-grown bladders in people, 
improving their urinary incontinence.157 He grew the bladders from the 
patients’ own urothelial cells to diminish the chance of the organs being 
rejected by the patients’ bodies.158 Atala is now helping a Pennsylvania-
based company called Tengion to conduct more studies of the bladder 
with the idea of eventually seeking federal approval to sell the organs 
commercially.159 While this is currently a mere thought, it can be 
inferred that the government would consider lab-grown organs to be 
“human organs”—hence, revealing why federal approval is needed. 
B. Interpreting Section 301 of NOTA: What Qualifies as “Valuable 
Consideration?” 
Intertwined with the interpretation of “bone marrow” under Section 
301 in Flynn v. Holder was what constitutes “valuable consideration.” 
The court upheld NOTA’s ban on the sale of body parts for transplant 
JOURNAL OF MEDICINE (2012), http://www.nejm.org/doi/full/10.1056/
NEJMp1114288?viewType=Print.  
 156.  Kao, supra note 118, at 1-2 (“[M]ost bone marrow stem cells are found in the bone 
marrow only, but a small number of them, called peripheral blood stem cells, also exist in the 
bloodstream.”).  
 157.  Steve Johnson, Lab-grown human organs: Companies lack funding to meet expectations, 
SAN JOSE MERCURY NEWS (Dec. 9, 2007 1:50 AM PST), http://www.mercurynews.com/
business/ci_7675722?nclick_check=1. 
158.  Id. 
159.  Id.  
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against plaintiffs who sought to incentivize bone marrow transplants by 
providing valuable consideration (a $3,000 housing subsidy, scholarship, 
or charitable donation) to donors.160 The Ninth Circuit upheld the law, 
“without applying heightened scrutiny to the statute, which would be 
required if the ban implicated a fundamental right, and found the statute 
constitutional after rational basis review.”161 Compensation for 
reasonable personal expenses associated with travel and lost wages is 
acceptable (as are paired living donor chains, since the 2007 amendment 
of NOTA) but any other “valuable consideration” that might incentivize 
sources of organs is not.162 
In Richards v. Holder, the Ninth Circuit held that plaintiff did not 
have a constitutional right to buy a kidney.163 In this case, plaintiff 
suffered from an end-stage renal disease and offered to pay $50,000 to a 
kidney donor to minimize the waiting time for a kidney.164 Plaintiff 
contended that NOTA violated his due process rights and exacted a 
taking without just compensation.165 The court rejected plaintiff’s 
contentions with Flynn v. Holder being the persuasive authority.166 In 
Flynn, the court upheld NOTA’s ban on compensation for human 
organs, noting that only a rational basis review was appropriate since 
NOTA did not involve a fundamental right.167 The Richards court again 
held the right to offer money for the donation of an organ for transplant 
not to be fundamental, and therefore, concluded that plaintiff could not 
nullify the statute.168 
While Flynn and Richards address the issues of whether the 
purchasing of an organ is a fundamental right, they also help clarify 
what is meant by “valuable consideration.” Flynn shows that the statute 
prohibits compensation of any kind, i.e. charitable, subsidy, or 
scholarship. Richards demonstrates that the statute prohibits direct 
payment of monies. Accordingly, intent is inconsequential; 
compensation is compensation. Therefore, if a 3D bioprinted organ is 
considered a “human organ” any form of compensation in exchange for 
160.  Flynn, 684 F.3d at 856.  
161.  Richards v. Holder, 2014 U.S. Dist. LEXIS 83431, 8 (D. Mass. June 19, 2014). 
162.  Michelle Meyer, HHS Proposes Rule to Amend NOTA, Nullify Flynn v. Holder, 
HARVARD LAW (Oct. 4, 2013), http://blogs.law.harvard.edu/billofhealth/2013/10/04/hhs-proposes-
rule-to-amend-nota-nullify-flynn-v-holder/.  
163.  Richards, 2014 U.S. Dist. LEXIS 83431 at 12. 
164.  Id. at 3.  
165.  Id. at 1.  
166.  Id. at 10. 
167.  Id. 
168.  Id. at 12. 
25
Smith: "Transplanting" Organ Donors with Printers
Published by IdeaExchange@UAkron, 2015
764 AKRON LAW REVIEW [49:739 
one will violate the statue. 
C. Interpreting Section 301 of NOTA: What Qualifies as “Interstate 
Commerce?” 
There are countless cases discussing the meaning of “interstate 
commerce.” However, there has been only one reported case related to 
organ trafficking in the United States.169 The district court in United 
States v. Wang charged defendants in a one count indictment with 
conspiracy to sell human organs for use in human transplants, in 
violation of 42 U.S.C. § 274(e).170 In this case, defendants attempted to 
sell human organs from executed Chinese prisoners in the United 
States.171 The indictment was not dropped because the charges set forth a 
jurisdictional basis between the alleged conspiracy and interstate 
commerce in the United States.172 The indictment stated that “the overt 
acts in furtherance of the alleged conspiracy occurred in the Southern 
District of New York and involved plans to sell organs in the United 
States.”173 Further, the court found that it was a part and object of the 
conspiracy that the defendants, “unlawfully, willfully and knowingly 
would acquire, receive and otherwise transfer organs from executed 
Chinese prisoners, for valuable consideration for use in human 
transplantation, which transfer would affect interstate commerce.”174 
D. Would 3D Bioprinted Organs Qualify as an Experimental Treatment? 
In Abigail Alliance for Better Access to Developmental Drugs v. 
Von Eschenbach, the United States Court of Appeals for the District of 
Columbia held that terminally ill, mentally competent patients who have 
exhausted all government-approved treatments do not have a 
fundamental right to experimental drugs that have only passed limited 
FDA safety trials.175 Any government regulation offending this right, 
 169.  Elizabeth Pugliese, Organ Trafficking and the TVPA: Why One Word Makes a Difference 
in International Enforcement Efforts, JOURNAL OF CONTEMPORARY HEALTH LAW & POLICY 
(2007), http://scholarship.law.edu/cgi/viewcontent.cgi?article=1111&context=jchlp.  
170.  United States v. Cheng Yong Wang, 1998 U.S. Dist. LEXIS 13481 (S.D.N.Y. Aug. 26, 
1998).  
171.  Id. 
172.  Id.  
173.  Id. at 8. 
174.  Id. at 5.  
175.  Byron R. Chin, Note, One Last Chance: Abigail Alliance v. von Eschenbach and the 
Right to Access Experimental Drugs, 41 U.C. DAVIS L. REV. 1969, 1972 (2008), available at 
http://lawreview.law.ucdavis.edu/issues/41/5/notes/41-5_Chin.pdf. 
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including the FDA approval process, is subject to a rational basis 
analysis, under which “only regulations with no demonstrable rational 
relationship to a legitimate state interest would be invalid.”176 
It is reasonable for terminally ill patients to want to undertake the 
risks associated with participating in a premarket drug study with the 
prospect that it could potentially save their lives.177 However, due to the 
stringent qualifications for engaging in such a study, many do not meet 
the criteria.178 These difficulties caused plaintiffs’ challenge to the FDA 
approval process.179 
To determine whether a fundamental right existed, the court first 
applied the Glucksberg test and looked to history and tradition to note 
the difference between drug safety and effectiveness.180 It found that the 
absence of government regulation alone failed to establish that the right 
was deeply rooted.181 Because a fundamental right was not implicated, 
the Abigail court applied a rational basis standard of review and 
determined that “the FDA’s interest in protecting patients from unsafe 
drugs bore a rational relationship to the challenged regulations.”182 Thus, 
the court granted the FDA’s motion to dismiss.183 With this holding, the 
court underscored “both the high hurdle that must be cleared to establish 
a right as fundamental and the deference due to legislatures in crafting a 
balance between the risks and benefits of medical technology where no 
fundamental right is implicated.”184 
The persuasive reasoning the court supplies in Abigail applies with 
176.  Id. 
177.  Id. at 1981. 
178.  Id.  
179.  Id. at 1982.  
180.  Id. at 1986. 
181.  Id. at 1987 
182.  Id. Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 
F.3d 695, 699 (D.C. Cir. 2007) (remarking that “terminally ill patients need not, however, always 
await the results of the clinical testing process.” “The FDA and Congress have created several 
programs designed to provide early access to promising experimental drugs when warranted. For 
example, under the ‘treatment IND’ program, the FDA may approve use of an investigational drug 
by patients not part of the clinical trials for the treatment of ‘serious or immediately life-threatening 
disease[s]’ if there exists ‘no comparable or satisfactory alternative drug or other therapy’; if ‘[t]he 
drug is under investigation in a controlled clinical trial’; and if the drug’s sponsor ‘is actively 
pursuing marketing approval of the investigational drug with due diligence.’ The FDA reserves the 
right, however, to deny any treatment IND request if (1) the agency believes there is no ‘reasonable 
basis’ to conclude that the drug is effective; or (2) granting the request ‘would . . . expose the 
patient . . . to an unreasonable and significant additional risk of illness or injury.’ Sponsors may not 
profit from any approved treatment IND program and may only ‘recover costs of manufacture, 
research, development, and handling of the investigational drug.’”). Id. 
183.  Id. 
184.  Richards v. Holder, 2014 U.S. Dist. LEXIS 83431, 11 (D. Mass. June 19, 2014). 
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greater force to the plaintiff’s challenge in Richards. In Abigail the law 
forbade the use of particular experimental drugs to plaintiffs who were 
terminally ill and without any other treatment options.185 By contrast, in 
Richards the law afforded plaintiff access to kidney transplants 
(although not without limitation), and he was availing himself of 
alternative treatment for his disease, specifically dialysis.186 Following 
the “high hurdle” required to implicate a fundamental right established 
by the Abigail court, the Ninth Circuit in Richards found the right to 
offer cash for a kidney donation for transplant not to be fundamental.187 
Abigail and Richards set forth an interesting distinction. The court 
in Abigail found that the terminally ill “do not have a fundamental right 
to experimental drugs that have passed [initial phase] clinical testing” 
and thus, denied the plaintiffs’ constitutional claim.188 The Richards 
court found that terminally ill individuals have a fundamental right to a 
kidney transplant; access was only denied because a transplant cannot be 
given in exchange for valuable consideration. This is an important 
difference because whether a printed organ qualifies initially as a 
“human organ” or an experimental treatment dictates how soon a patient 
can receive a transplant. In the future, if the first printed organs are 
considered “human organs,” they are immediately ready for implantation 
and saving lives. However, if the first printed organs must undergo 
clinical testing, and are therefore at that point in time considered 
experimental, a patient would not have a fundamental right to the 
bioprinted organs until they have progressed past the initial phase of 
testing. 
Since an organ is created artificially through the use of a 3D printer, 
it could be argued either that it is experimental medical treatment or is a 
true organ because it functions necessarily the same as a naturally 
occurring organ. One way to analyze this new technology is in 
comparison to in vitro organogenesis, which was a precursor to 3D 
organ printing.189 This area of development has already progressed into 
185.  Id. at 10. 
186.  Id. 
187.  Id. at 12. 
188.  Id. at 11. 
189.  Definition of In vitro, MEDICINENET.COM (Mar. 19, 2012), 
http://www.medicinenet.com/script/main/art.asp?articlekey=4033 (explaining that in vitro 
organogenesis is a method for regenerating organs from stem cells in a test tube or other laboratory 
vessel outside of a living organism.); see also Drew Halley, Growing Organs in the Lab, 
SINGULARITY UNIVERSITY (June 8, 2009), http://singularityhub.com/2009/06/08/growing-organs-
in-the-lab/ (stating that this technology requires precise blueprints for each cell-differentiation step 
and that this method has already seen some promising results such as the generation of a bladder, 
which is in Phase II testing, meaning that it has already been implanted into individuals and studied 
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clinical testing, which is a strong indicator that 3D printing will also 
have to endure clinical testing, and thus, fits with the court’s holding in 
Abigail. It is likely that even if an individual is terminally ill with no 
alternative treatment options, a 3D printed organ will not be a treatment 
option until it has completed initial clinical testing and proven safe and 
effective.190 This dampens the almost-immediate gratification outlook 
for 3D printed organs, since clinical testing can take several years.191 
E. Ethical Considerations of 3D Bioprinting 
It is quite possible that with the arrival of 3D bioprinting, there will 
come black market operations for the purchase of bioprinted organs. 
Indeed, Facebook has already been an instrument used for selling black 
market organs.192 While this contemplation hinges on whether a printed 
organ is indeed a “human organ,” it is likely that it will be, and 
therefore, is a topic that should not be ignored. 
A 2012 report from the World Health Organization showed that 
more than one human organ is illegally purchased every hour 
worldwide, with the majority being kidneys.193 Donors can include 
impoverished villagers, funeral home directors, and even victims of sex-
how the body adapts to it).  
 190.  Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 
695, 698 (D.C. Cir. 2007) (“Clinical testing for safety and effectiveness requires three or sometimes 
four phases.). See Food and Drug Administration, Department of Health and Human Services 
Investigantional New Drug Application, 21 C.F.R. § 312.21(a)(1) (discussing that Phase I involves 
the initial introduction of a new drug into human subjects. A Phase I study usually consists of 
twenty to eighty subjects and is “designed to determine the metabolism and pharmacologic actions 
of the [new] drug in humans, the side effects associated with increasing doses, and, if possible, to 
gain early evidence on effectiveness.”). § 312.21(b) (stating that Phase II studies are “well 
controlled” and “closely monitored” clinical trials of no more than several hundred subjects, used to 
evaluate both the “effectiveness of the drug for a particular indication” and its “common short-term 
side effects and risks.”). § 312.21(c) (explaining that Phase III studies are expanded clinical trials to 
“gather the additional information about effectiveness and safety that is needed to evaluate the 
overall benefit-risk relationship of the drug and to provide an adequate basis for physician 
labeling.”). 21 U.S.C.A. § 355(n)(1) (West, Westlaw through P.L. 114-114 (excluding 114-92, 114-
94, 114-95 and 114-113) approved 12-28-2015) (noting that to guide the clinical testing process, 
Congress has directed the FDA to establish “[s]cientific advisory panels” to “provid[e] expert 
scientific advice and recommendations to the Secretary regarding a clinical investigation of a drug 
or the approval for marketing of a drug.”).  
 191.  The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, U.S. FOOD 
AND DRUG ADMINISTRATION (Nov. 6, 2014), http://www.fda.gov/drugs/resourcesforyou/
consumers/ucm143534.htm.  
 192.  Emily Thomas, Black Market For Organs Reportedly Alive And Well On Facebook, THE 
HUFFINGTON POST (Mar. 10, 2014), http://www.huffingtonpost.com/2014/03/10/kidneys-sold-
online-facebook-organ-donors_n_4936216.html.  
193.  Id. 
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trafficking or kidnapping.194 Each of these groups includes people who 
have direct access to organs. However, with 3D bioprinting the pool can 
expand enormously. There would no longer be such a limitation. Anyone 
who could afford to purchase a printer, was appropriately trained, and 
had access to appropriate cells could in theory start their own black 
market brigade. Bottom-line, anyone with the motivation and time could 
establish an unlawful business. 
Would this necessarily be a bad thing? If Congress were to amend 
NOTA to explicitly allow the selling of manufactured organs under 
controlled circumstances, it would eliminate these ethical issues. 
Because 3D bioprinting could create a surplus of manufactured organs, 
printed organs could be treated like any other living commodity, such as 
bananas, trees, and dogs. Notably, there is no law prohibiting the 
exchange of a dog for valuable consideration. No lives would have to be 
compromised, no family members would have to make sacrifices, and 
there would be no concern of atrophy of organ tissue. If a printed organ 
were to die, a new one could be printed out. 
In theory, once 3D bioprinted organs are widely available, there 
would no longer be a use for donated organs for transplant. As a result, 
NOTA could be repealed. This would eliminate any confusion over 
regulating donated versus manufactured organs, eradicating any concern 
for black-market businesses. The process of organ transplantation could 
become as basic and routine as a tonsillectomy. 
V. CONCLUSION 
Section 301 of NOTA prohibits the purchase of human organs 
stating that “it shall be unlawful for any person to knowingly acquire, 
receive or otherwise transfer any human organ for valuable 
consideration for use in human transplantation if the transfer affects 
interstate commerce.” This Note concludes that it is likely that selling 
3D printed organs would be a federal offense. The court’s treatment of 
the aspiration method in Flynn v. Holder and the analysis of federal 
approval for lab-grown organs bolsters the interpretation that a 
manufactured organ would be considered a “human organ.” The Ninth 
Circuit decisions in Flynn v. Holder and Richards v. Holder provide 
helpful insight into construction of “valuable consideration” under 
NOTA, suggesting that no compensation of any kind could be given in 
exchange for a bioprinted organ, including money, subsidies, 
194.  Id. 
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scholarships, or other charitable donations. Further, the court in Flynn v. 
Holder concluded that it is not a deprivation of life and liberty without 
due process of law to forbid the purchase of an organ, even under an 
end-stage disease situation. Similarly, the definition of “interstate 
commerce” under NOTA can be interpreted as commerce between any 
state or territory or any place outside thereof (“but only insofar as such 
commerce takes place within the United States”).195 While this does not 
cover intrastate commerce, all 50 states have adopted the UAGA that 
makes it unlawful to purchase or sell organs within that state. Based on 
the definitions provided in Section 301 and common law, it is likely that 
selling or purchasing a completed 3D printed organ anywhere in the 
United States would violate NOTA. 
Unfortunately, the ethical ramifications of 3D bioprinting might 
detract from the benefits it promises to offer. While the use of 3D 
bioprinting could eventually save lives, until the federal government 
approves it, private creation and selling of 3D bioprinted organs would 
exacerbate organ selling on the black market. If Congress were to amend 
NOTA, however, to allow for the selling and purchasing of 3D printed 
organs, this could eliminate such black market activity. 
Optimistically, after successful clinical testing and federal approval, 
3D bioprinting could ultimately create a surplus of transplantable organs, 
and more importantly, make organs a widely available commodity by 
eliminating the donor. If John Wallis were to publish the “New, New 
Game of Life” today, it would likely include a few, bonus intermittent 
stages of life: Maybe an organ transplantation for a body tune-up to 
revert back to the prime of your life or a transplantation to escape death. 
With 3D bioprinting, the possibilities are endless and ultimately will 
allow the game of life to play on. 
 195.  Commerce and Trade Definitions, 15 U.S.C. § 717a (2015) (Although not a part of the 
Federal Food, Drug, and Cosmetic Act, this section of the U.S. Code gives further insight into what 
Congress likely meant by “any place outside thereof.”). 
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